--- title: "Sonoma Pharma Prices $4 Mln Offering Of Shares And Warrants" type: "News" locale: "en" url: "https://longbridge.com/en/news/284192986.md" description: "Sonoma Pharmaceuticals, Inc. (SNOA) has priced a $4 million offering of 2.96 million shares and warrants at $1.35 each. The proceeds will be used for general corporate purposes, including working capital. The offering is set to close on April 27, 2026, pending customary conditions. Additionally, Dawson James Securities has a 45-day option to purchase up to 15% of the offering to cover over-allotments. SNOA's stock closed at $1.14, down 36.67%, and is down 0.86% in pre-market trading." datetime: "2026-04-27T10:10:28.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284192986.md) - [en](https://longbridge.com/en/news/284192986.md) - [zh-HK](https://longbridge.com/zh-HK/news/284192986.md) --- # Sonoma Pharma Prices $4 Mln Offering Of Shares And Warrants (RTTNews) - Sonoma Pharmaceuticals, Inc. (SNOA) priced a $4 million offering of 2.96 million shares and 2.96 million warrants. The offering is priced at $1.35 per share, and the warrants have an exercise price of $1.35 per share. The company expects to use the net proceeds from the offering for general corporate purposes, including working capital. The offering is expected to close on April 27, 2026, subject to customary closing conditions. In addition, Sonoma Pharma has granted Dawson James Securities a 45-day option to purchase up to 15% of the number of shares or warrants sold in the offering solely to cover over-allotments, if any. Sonoma Pharma develops stabilised hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. SNOA has traded between $0.85 and $6.92 over the last year. The stock closed Friday's trade at $1.14, down 36.67%. In the pre-market, SNOA is down 0.86% to $1.13. For More Such Biotech Stock News, visit rttnews.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ### Related Stocks - [SNOA.US](https://longbridge.com/en/quote/SNOA.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md) ## Related News & Research - [](https://longbridge.com/en/news/286807703.md) - [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md) - [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md) - [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md) - [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)